TIRZEPATIDE — Dual GIP & GLP-1 Receptor Agonist

Advanced Metabolic Research | Glucose Regulation | Weight Management

Product Overview

Tirzepatide is a synthetic peptide and dual receptor agonist that simultaneously activates glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.

Developed by Eli Lilly and commercially available as Mounjaro®, tirzepatide is an approved once-weekly injectable prescription medicine used for the management of type 2 diabetes and, in eligible adults, obesity or overweight accompanied by weight-related health conditions.

Its dual-action mechanism has attracted significant scientific interest due to its effects on appetite regulation, glucose metabolism, insulin secretion, and body weight.

Mechanism of Action

Tirzepatide acts through two complementary metabolic pathways:

• GIP Receptor Activation: Enhances glucose-dependent insulin secretion and contributes to metabolic regulation.

• GLP-1 Receptor Activation: Promotes satiety, reduces appetite, supports insulin secretion, and influences gastric emptying.

• Glucose Homeostasis: Helps regulate blood glucose levels through glucose-dependent hormonal mechanisms.

• Body Weight Regulation: Reduced appetite and energy intake can contribute to substantial weight reduction in eligible patients.

Clinical Research & Applications

Clinical studies have demonstrated significant improvements in glycemic control and body weight among studied populations.

Key research areas include:

• Type 2 Diabetes: Investigation and clinical management of blood glucose regulation.

• Obesity and Weight Management: Evaluation of body weight reduction and long-term weight maintenance.

• Appetite Regulation: Examination of incretin-related signaling pathways involved in hunger and satiety.

• Metabolic Health: Research into insulin sensitivity, energy balance, and cardiometabolic risk factors.

Regulatory Status & Safety

Tirzepatide is an approved prescription medicine in the European Union, including Portugal, for specific clinical indications.

Approved medicinal products are subject to pharmaceutical manufacturing standards, quality controls, and regulatory oversight.

Common adverse reactions include nausea, diarrhea, vomiting, constipation, and other gastrointestinal symptoms. More serious risks and precautions are described in the official prescribing information.

The safety, purity, and effectiveness of independently manufactured or research-labeled tirzepatide preparations cannot be assumed to be equivalent to those of approved medicines.

Research Use Only

FOR LEGITIMATE SCIENTIFIC AND LABORATORY RESEARCH PURPOSES ONLY.

Research materials are intended exclusively for qualified professionals conducting authorized scientific investigations.

Research-labeled preparations are not approved medicinal products and must not be used for human or veterinary administration, personal injection, or self-medication.

A “Research Use Only” designation does not override pharmaceutical regulations or authorize the commercial supply of an unapproved injectable medicine for human use.

PEPTITAN — PRECISION. SCIENCE. RESEARCH.